Research Article
Prognostic Role of MicroRNA-126 for Survival in Malignant Tumors: A Systematic Review and Meta-Analysis
Table 1
Main characteristics of enrolled studies in the systematic review.
| Author | Year | Country | Cancer | Number | Specimen | Assay | Cut-off value | Source of HR | Endpoint | Median follow-up (months) |
|
Shibayama et al. [36] | 2015 | Japan | AML | 108 | Bone marrow | qRT-PCR | Median | R | OS | NR | Ishihara et al. [37] | 2012 | Japan | ATL | 35 | Plasma | qRT-PCR | Median | SC | OS | NR | de Leeuw et al. [38] | 2014 | Netherlands | AML | 92 | Blood | qRT-PCR | Median | R | OS, EFS, RFS | NR | Sanfiorenzo et al. [39] | 2013 | France | NSCLC | 52 | Plasma | qRT-PCR | Median | R | DFS | 46 | Donnem et al. [40] | 2011 | Norway | NSCLC | 332 | Tissue | ISH | Expression score ≥ 2 | R | DSSa | 86 | Kim et al. [41] | 2014 | South Korea | NSCLC | 72 | Tissue | qRT-PCR | Median | R | OS | 31 | Jusufović et al. [42] | 2012 | Serbia | NSCLC | 50 | Tissue | qRT-PCR | Median | R | OS, PFS | 5.13 | Yang et al. [43] | 2012 | China | NSCLC | 442 | Tissue | qRT-PCR | Median | R | OS | 24.39–29.28 |
Li et al. [44] | 2014 | China | NSCLC | 49 | Tissue | qRT-PCR | Median | SC | OS, DFS | 39 | Han et al. [45] | 2012 | China | HCC | 105 | Tissue | qRT-PCR | Fold change = 2 | R | OS | 42.89 | Chen et al. [46] | 2013 | China | HCC | 68 | Tissue | qRT-PCR | 0.70 (ROC curve) | SC | OS | 49 | Yang et al. [47] | 2014 | China | Cervical cancer | 133 | Tissue | qRT-PCR | Median | R | OS | 60 (max) | Sun et al. [48] | 2014 | China | LSCC | 38 | Plasma | qRT-PCR | Median | SC | OS | NR | Hansen et al. [49] | 2012 | Denmark | CRC | 89 | Tissue | ISH | Median | SC | PFS | 16.8–26.2 | Hansen et al. [50] | 2014 | Denmark | CRC | 63 | Plasma | qRT-PCR | Median | R | PFS | 8.8–9.2 |
Li et al. [51] | 2013 | China | Colon cancer | 53 | Tissue | ISH | 0/1–3+ | SC | OS | 45.66–55.04 | Liu et al. [52] | 2014 | China | CRC | 92 | Tissue | qRT-PCR | Median | SC | OS | 65 | Díaz et al. [53] | 2008 | Spain | Colon cancer | 110 | Tissue | qRT-PCR | Median | R | OS, DFS | 68 | Hansen et al. [54] | 2011 | Denmark | CRC | 81 | Tissue | ISH | Median | R | OS, PFS | NR | Hansen et al. [55] | 2013 | Denmark/Sweden | CRC | 89 | Tissue | qRT-PCR | Median | R | PFS | NR | Hansen et al. [56] | 2015 | Denmark | CRC | 560 | Tissue | qRT-PCR | Median | R | OS, DSS | 7 years (max) | Sasahira et al. [57] | 2012 | Japan | Oral cancer | 94 | Tissue | qRT-PCR | Means | R | DFS | 3.4 years | Sun et al. [58] | 2013 | China | Prostate cancer | 128 | Tissue | qRT-PCR | Median | SC | RFS | 3–10 years | Hoppe et al. [59] | 2013 | Germany | Breast cancer | 80 | Tissue | qRT-PCR | 6.20 (ROC curve) | R | RFS | 8.84 years | Vergho et al. [60] | 2014 | Germany | cRCC | 37 | Tissue | qRT-PCR | 3.57 (ROC curve) | R | DSS | 41.4 | Khella et al. [61] | 2015 | Canada | cRCC | 257,481b | Tissue | qRT-PCR | 20th percentile | R | OS, DFS, OSb | 48.6 | Liu et al. [62] | 2015 | China | ESCC | 185 | Tissue | ISH | Fold change > 3 | R | DSS | 32 | Hu et al. [63] | 2011 | USA | ESCC | 158 | Tissue | ISH | 1–3+/0–0.5 | R | OS, DFS | 16.25 | Wang et al. [64] | 2013 | China | ESCC | 116 | Tissue | qRT-PCR | CT < −1 | SC | DFS | 21–32 | Feng et al. [65] | 2012 | USA | GBM | 248 | Tissue | qRT-PCR | Median | R | PFS/RFSb, OSb | NR |
|
|
CRC: colorectal cancer; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; cRCC: clear renal cell carcinoma; ESCC: esophageal squamous cell carcinoma; AML: acute myeloid leukemia; ATL: adult T-cell leukemia; LSCC: laryngeal squamous cell carcinoma; GBM: glioblastoma multiforme; qRT-PCR: quantitative real-time PCR; ISH: in situ hybridization; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; PFS: progression-free survival; DSS: disease-specific survival; HR: hazard ratio; SC: survival curve; NR: not reported; R: reported. aDSS included any of the following: DSS, CSS (cancer-specific survival). bData extracted from TCGA (The Cancer Genome Atlas) in the paper.
|